BUZZ-Nutanix rallies ahead of S&P MidCap addition
I'm PortAI, I can summarize articles.
Nutanix shares rose 5.6% to $73.85 as the company prepares to join the S&P MidCap 400 later this month, replacing Acadia Healthcare. This marks the fourth consecutive session of gains for Nutanix, reaching a one-month high. The stock has increased approximately 21% year-to-date, outperforming the Nasdaq Composite. Analysts remain optimistic, with 17 of 19 rating it as a "strong buy" or "buy," and a median price target of $90.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments